Every material Form 8-K Solventum filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Solventum reported third-quarter 2025 sales of $2.1 billion, up 0.7% (2.7% organic), while adjusted diluted EPS fell 8.5% to $1.50. The company raised its full-year adjusted EPS range to $5.98 to $6.08 from $5.88 to $6.03 and launched a multiyear Transform for the Future program, which it expects to generate about $500 million in annual cost savings, though GAAP diluted EPS of $7.22 includes a $1.5 billion gain on the Purification and Filtration sale.
Q3 net sales $2,096 million, up 0.7%; organic sales up 2.7%
Adjusted diluted EPS $1.50 versus $1.64 a year earlier, down 8.5%; GAAP diluted EPS $7.22
Full-year adjusted EPS outlook raised to $5.98 to $6.08; free cash flow guidance revised to $150 million to $250 million
Transform for the Future expected to yield about $500 million in annual savings with about $500 million in cumulative pretax costs
Solventum appointed Heather Knight to a newly created Chief Commercial Officer role, effective November 10, 2025, where she will oversee global commercial and R&D operations across its MedSurg, Dental Solutions and Health Information Systems segments. Chris Barry, Executive Vice President and Group President of MedSurg, will leave the company effective December 31, 2025, and may receive severance if he signs a general release. The filing gives no financial impact figures, but the leadership change restructures commercial oversight for shareholders.
Heather Knight becomes Chief Commercial Officer effective November 10, 2025, reporting directly to CEO Bryan Hanson
Knight previously served as Chief Operating Officer at Baxter International and has over 30 years of MedTech experience
Chris Barry, EVP and Group President of MedSurg, departs effective December 31, 2025
Barry may receive severance under the Solventum Executive Severance Plan, subject to a signed general release
Solventum completed the sale of its Purification & Filtration business to Thermo Fisher Scientific on September 1, 2025, for approximately $4.0 billion in cash before adjustments. The company said net proceeds of $3.4 billion will be used primarily to pay down debt, and it raised its adjusted EPS guidance for 2025, which shareholders may view as a positive development.
Sale closed September 1, 2025; cash consideration was approximately $4.0 billion, subject to closing adjustments, and Solventum may pay Buyer up to $75 million
Net proceeds of $3.4 billion will be used primarily to pay down outstanding debt
Adjusted EPS guidance raised to $5.88 to $6.03 from $5.80 to $5.95
Expected net interest expense lowered to $400 million from $450 million; organic sales growth (+2.0% to +3.0%) and free cash flow ($450 million to $550 million) guidance unchanged
Solventum reported second-quarter 2025 net sales up 3.9% to $2.2 billion, with adjusted diluted EPS of $1.69 versus $1.56 a year earlier. The company raised its full-year 2025 adjusted EPS outlook to $5.80-$5.95 and its organic sales growth outlook to 2.0%-3.0%, but GAAP operating income margin and quarterly free cash flow declined.
Q2 net sales rose 3.9% to $2.2 billion; organic sales rose 2.8%.
Adjusted diluted EPS was $1.69, up 8.3%; GAAP diluted EPS was $0.51, flat year over year.
Full-year adjusted EPS outlook raised to $5.80-$5.95 from $5.45-$5.65; organic sales growth outlook raised to +2.0% to +3.0%.
GAAP operating income margin fell to 9.9% from 11.7%; Q2 free cash flow was $59 million versus $297 million.
On June 25, 2025, Solventum and Thermo Fisher signed an amended agreement that removes Solventum's drinking water filtration business from the planned sale and lowers the cash payment at closing from about $4.10 billion to about $4.00 billion. Solventum says the change could simplify the deal and speed up its closing, which it still expects by the end of 2025, but it will also reduce previously projected gross and operating margin improvements.
Cash consideration at closing falls from about $4.10 billion to about $4.00 billion; net proceeds are still intended mainly to pay down debt.
The Water Business is excluded, and Thermo Fisher may receive up to $75 million from Solventum on a sale of that business or after a 3-year period.
Previously projected gross margin (200 basis points) and operating margin (100 basis points) improvements will be reduced; updated estimates will come on the second-quarter earnings call.
Solventum reported first-quarter 2025 sales up 2.6% to $2.1 billion, with organic sales up 4.3%. Profit fell sharply: net income was $137 million versus $237 million a year earlier, and GAAP diluted EPS was $0.78 versus $1.37. The company raised its full-year 2025 organic sales growth outlook to +1.5% to +2.5% but left its adjusted EPS and free cash flow guidance unchanged.
Net sales rose 2.6% to $2.1 billion; organic sales rose 4.3% for the quarter.
GAAP diluted EPS was $0.78 versus $1.37; adjusted diluted EPS was $1.34 versus $2.08.
Free cash flow was negative $80 million versus $340 million a year earlier.
Full-year organic sales growth outlook raised to +1.5% to +2.5% from +1.0% to +2.0%; adjusted EPS guidance of $5.45 to $5.65 unchanged.
Solventum agreed on February 25, 2025 to sell its purification and filtration business to Thermo Fisher Scientific for approximately $4.10 billion in cash, plus assumption of certain liabilities, subject to customary closing adjustments. The deal is subject to closing conditions, including antitrust clearance, and Solventum expects to close by the end of 2025, so shareholders face a pending divestiture rather than a completed sale.
Cash consideration of approximately $4.10 billion payable at closing, subject to adjustments for cash, debt, transaction expenses and working capital
Agreement dated February 25, 2025; Solventum expects to close by the end of the 2025 calendar year
Either party may terminate if the deal is not completed by November 25, 2025, with two three-month extensions available if only regulatory conditions remain unmet
Solventum agreed to a three-year non-compete for the business and a two-year non-solicit and no-hire for certain employees after closing
Solventum reported fourth-quarter 2024 sales up 1.9% to $2.074 billion, but GAAP diluted EPS fell to $0.17 from $1.57 a year earlier, and adjusted EPS fell to $1.41 from $2.17. The company also introduced 2025 guidance for organic sales growth, adjusted EPS and free cash flow, but said the guidance still includes the Purification and Filtration segment it agreed to sell and will be updated after that deal closes.
Q4 2024 sales were $2.074 billion, up 1.9%; organic sales rose 2.3%
GAAP operating income was $136 million versus $406 million a year earlier; adjusted operating margin was 20.4% versus 25.9%
2025 guidance: organic sales growth of 1.0% to 2.0%, adjusted EPS of $5.45 to $5.65, free cash flow of $450 million to $550 million
Guidance includes Purification and Filtration, which Solventum announced it would sell on February 25, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Solventum filing is on SEC EDGAR ↗. 8-K briefs of other companies →